Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Fig. 3

Use of OCS over time in OCS-dependent patients (n = 53). (A) Mean OCS dose reduction at 1 year of FUP. (B) Estimated mean cumulative OCS exposure over 1 year of FUP for patients continuing on study-entry mean OCS dose compared with patients treated with benralizumab and reducing the OCS dose after 1 year of FUP. FUP, follow-up; OCS, oral corticosteroids

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us